Impact of CDKN2A gene expression on colon adenocarcinoma via biosignature analysis

Chen Xu
DOI: https://doi.org/10.1097/md.0000000000039408
IF: 1.6
2024-11-08
Medicine
Abstract:Colon adenocarcinoma, a common digestive system tumor, has become more prevalent over the past 10 years. Among the 36 types of malignant tumors in 185 countries (regions) in 2020, colon adenocarcinoma ranks fifth. [ 1 ] In recent years, colon adenocarcinoma has become the second most common cause of adenocarcinoma in China, showing a trend towards younger patients. [ 2 , 3 ] As the early symptoms of colon adenocarcinoma are not obvious, most cases are detected in advanced stages, and the optimal surgical opportunity is missed. Therefore, there is an urgent need to identify key markers for targeted interventions and establish safer and more effective treatment methods. Cyclin-dependent kinase inhibitor 2A (CDKN2A), located on chromosome 9p21, is a tumor suppressor gene that normally participates in cell cycle regulation and prevents cell proliferation. [ 4 , 5 ] The CDKN2A protein contains 156 amino acids that regulate cell proliferation and inhibit tumor generation in the cell cycle. Inactivation of this gene can lead to the control of cell separation and malignant progression to tumors; however, the specific mechanism remains unclear. [ 6 , 7 ] However, the relationship between the expression of CDKN2A and prognosis and pathological features of colon adenocarcinoma remains unclear. Herein, based on several large public bioinformatics databases, we performed an in-depth and comprehensive analysis of the potential value of CDKN2A as a clinical marker and immunotherapeutic target for colorectal adenocarcinoma (COAD).
medicine, general & internal
What problem does this paper attempt to address?